Majority of Dermatologists in US Prescribe Baricitinib to Patients With Alopecia Areata, Report Shows
Bariticinib (Olumiant; Eli Lilly) is prescribed by the majority of US dermatologists to their patients with alopecia areata (AA), according...
Dermatology Market Research, Studies & Insights
Spherix Global Insights’ Dermatology therapeutic team is a leading provider of independent syndicated dermatology market research, insights & business intelligence.
On an annual basis, Spherix’s Dermatology team publishes over 36 studies in seven different indication areas including: atopic dermatitis, plaque psoriasis, alopecia areata, hidradenitis suppurativa, prurigo nodularis and vitiligo.
Unparalleled Dermatology Therapeutic Expertise
Our team of dermatology experts delivers insights to pharmaceutical, life sciences, and biotechnology companies derived from dermatologists, healthcare providers & professionals, key opinion leaders, and the entire life sciences community. Insights from these experts help inform your product development and go-to-market strategies, helping you stay patient-focused at every step of the process.
Spherix Global Insights Dermatology – Your Trusted Advisor
Our clients are facing unprecedented challenges globally and must have the scientific, commercial, and operational capabilities necessary to thrive in an increasingly complex health care environment. As a trusted advisor, Spherix’s Dermatology syndicated market research studies empower our clients to innovate, thrive, and grow from development to launch.
Follow Spherix Dermatology on Social Media
Follow us for dermatology industry news, insights & analysis:
Twitter: https://twitter.com/SpherixDerm
LinkedIn: https://www.linkedin.com/company/spherix-global-insights/
For Guests & Current Clients
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com
Dr. Alan Menter was born in England and is a graduate of the Medical School of the University of Witwatersrand, South Africa. He completed his dermatology residency at Pretoria General Hospital at the University of Pretoria, also in South Africa, and two fellowships in London at Guy's Hospital and St. John's Hospital for Diseases of the Skin. A fellowship with the University of Texas Southwestern Medical Center in Dallas brought Menter to the United States in 1975. Since then, he has held several positions within the UT and Baylor University Dallas systems. In 1992, he was appointed chairman of the Division of Dermatology at Baylor University Medical Center and still holds that position. In 2007, he was appointed director of the Baylor Research Center and in 2010, Program Director of the newly formed Dermatology Residency Program at Baylor University Medical Center.
Joseph F. Merola, MD, MMSc, is Associate Professor in the Department of Dermatology and Department of Medicine, Division of Rheumatology at Harvard Medical School in Boston, Massachusetts. Dr. Merola is board-certified in Dermatology, Internal Medicine, and Rheumatology. He serves as the Vice Chair for Clinical Trials, the Director of the Clinical Unit for Research Innovation and Trials (CUReIT), Director of the Center for Skin and Related Musculoskeletal Diseases and the Associate Program Director for the Harvard Combined Internal Medicine-Dermatology Residency Training Program at Brigham and Women’s Hospital in Boston. Dr. Merola earned his medical degree at New York University School of Medicine in New York, New York, followed by his Master of Medical Sciences degree at Harvard Medical School. He completed an internship in Internal Medicine at the Hospital of the University of Pennsylvania in Philadelphia, followed by a residency in Dermatology at New York University Medical Center. He continued with a residency in Internal Medicine and a fellowship in Rheumatology at Brigham and Women’s Hospital.
Dr. Patel-Cohen is a dermatologist specializing in autoinflammatory disease of the skin, with a focus on hidradenitis suppurativa. She completed a unique fellowship in Dermatology-Rheumatology at Brigham and Women's Medical Center. She is currently the Director of Complex Medical Dermatology at Summit Medical Group. Prior to joining Summit Medical Group, Dr. Patel-Cohen was an attending physician at Brigham and Women's Hospital and an assistant professor at Harvard Medical School. She was the founder and director of Brigham and Women's Hidradenitis Suppurativa and Neutrophilic Dermatoses Clinic and their Dermatology-Gastroenterology multidisciplinary clinic.
Dr. Blauvelt is President of Oregon Medical Research Center, a small business dedicated to performing high quality clinical research studies in dermatology. He received his undergraduate degree in electrical engineering at Purdue University, his medical degree at Michigan State University, and a healthcare MBA at Oregon Health & Science University (OHSU). Dr. Blauvelt trained in dermatology at the University of Miami and in cellular immunology under the direction of Dr. Steve Katz at the National Institutes of Health (NIH). Earlier in his career, he held senior staff positions at the NIH (Senior Investigator), OHSU (Professor), and the Portland VA Medical Center (Chief). Dr. Blauvelt's research and clinical expertise has been in Langerhans cell biology, T cell immunology, virology, psoriasis, and atopic dermatitis. He has published over 300 papers and spoken across the country and world on these topics. Within psoriasis research, his laboratory published key papers on the role of IL-23/Th17 biology in psoriasis; in recent years, he has been the international lead investigator on a number of important clinical trials, including PSTELLAR, FEATURE, IXORA-R, VOYAGE 1, IMMhance, CHRONOS, ECZTEND, JADE REGIMEN, and HEADS UP. Dr. Blauvelt is also an elected member of the American Society for Clinical Investigation, the International Psoriasis Council, the International Eczema Council, and the Scientific Advisory Committee of the National Psoriasis Foundation. In 2021, he made the list of Highly Cited Researchers, representing the top 1% of cited scientists in the world.
Bariticinib (Olumiant; Eli Lilly) is prescribed by the majority of US dermatologists to their patients with alopecia areata (AA), according...
Despite little prescriber differentiation between the JAKs, including satisfaction and manufacturer perceptions, Olumiant is projected to maintain a significant market...
Boehringer Ingelheim’s Cyltezo has a slight competitive edge over other concurrent biosimilar launches on certain key performance metrics, though prescriber...
Amgen’s $13.4 billion Otezla bet can withstand competition from Bristol Myers Squibb’s Sotyktu. That is the conclusion of analysts at...